Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iqbal Mahmud

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
British Journal of Cancer|October 11, 2024
Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanomaChandrani Chattopadhyay, Janos Roszik, Rajat Bhattacharya, et al.
Nature Cancer|May 13, 2025
CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumorsFeiyu Chen, Haoyan Li, Yin Wang, et al.
Cancers|June 26, 2026
The Imipridone ONC206 Inhibits Tumor Growth and Improves Survival in Patient-Derived Xenograft Models of Uveal MelanomaMir Mustafa Ali, Md Alauddin, Iqbal Mahmud, et al.
Nature Communications|February 9, 2026
High-throughput multi-organ proteomics workflow for drug efficacy and toxicity analysisYun Xiong, Lin Tan, Wai-Kin Chan, et al.
Cancers|May 16, 2023
Immune Profile of Exosomes in African American Breast Cancer Patients Is Mediated by Kaiso/THBS1/CD47 SignalingMd Shakir Uddin Ahmed, Brittany D Lord, Benjamin Adu Addai, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
CerS2 is a druggable target in triple-negative breast cancerHissah Alatawi, Haritha H Nair, Lingbao Ai, et al.
Molecular Cancer Therapeutics|April 21, 2026
CerS2 is a druggable target in triple-negative breast cancerHissah Alatawi, Haritha H Nair, Lingbao Ai, et al.
Research Square|October 27, 2023
Augmenting Mitochondrial Respiration in Immature Smooth Muscle Cells with an <i>ACTA2</i> Pathogenic Variant Mitigates Moyamoya-like Cerebrovascular DiseaseAnita Kaw, Ting Wu, Zbigniew Starosolski, et al.
Blood|February 6, 2025
Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myelomaLi Qin, Luz Yurany Moreno Rueda, Upasana Ray, et al.
Nature Communications|July 2, 2025
Immature Acta2<sup>R179C/+</sup> smooth muscle cells cause moyamoya-like cerebrovascular lesions in mice prevented by boosting OXPHOSAnita Kaw, Suravi Majumder, Jose E Esparza Pinelo, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
British Journal of Cancer|October 11, 2024
Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanomaChandrani Chattopadhyay, Janos Roszik, Rajat Bhattacharya, et al.
Nature Cancer|May 13, 2025
CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumorsFeiyu Chen, Haoyan Li, Yin Wang, et al.
Cancers|June 26, 2026
The Imipridone ONC206 Inhibits Tumor Growth and Improves Survival in Patient-Derived Xenograft Models of Uveal MelanomaMir Mustafa Ali, Md Alauddin, Iqbal Mahmud, et al.
Nature Communications|February 9, 2026
High-throughput multi-organ proteomics workflow for drug efficacy and toxicity analysisYun Xiong, Lin Tan, Wai-Kin Chan, et al.
Cancers|May 16, 2023
Immune Profile of Exosomes in African American Breast Cancer Patients Is Mediated by Kaiso/THBS1/CD47 SignalingMd Shakir Uddin Ahmed, Brittany D Lord, Benjamin Adu Addai, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
CerS2 is a druggable target in triple-negative breast cancerHissah Alatawi, Haritha H Nair, Lingbao Ai, et al.
Molecular Cancer Therapeutics|April 21, 2026
CerS2 is a druggable target in triple-negative breast cancerHissah Alatawi, Haritha H Nair, Lingbao Ai, et al.
Research Square|October 27, 2023
Augmenting Mitochondrial Respiration in Immature Smooth Muscle Cells with an <i>ACTA2</i> Pathogenic Variant Mitigates Moyamoya-like Cerebrovascular DiseaseAnita Kaw, Ting Wu, Zbigniew Starosolski, et al.
Blood|February 6, 2025
Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myelomaLi Qin, Luz Yurany Moreno Rueda, Upasana Ray, et al.
Nature Communications|July 2, 2025
Immature Acta2<sup>R179C/+</sup> smooth muscle cells cause moyamoya-like cerebrovascular lesions in mice prevented by boosting OXPHOSAnita Kaw, Suravi Majumder, Jose E Esparza Pinelo, et al.
Pageof 7